GD1 has led a $30M Series A Expansion Round for Alimetry, a pioneering health tech startup revolutionizing gastrointestinal diagnostics with a non-invasive solution.

Information on the Target

Alimetry is an innovative health tech startup focused on revolutionizing the diagnosis of gastrointestinal disorders. Founded by distinguished experts Prof. Greg O’Grady and Dr. Armen Gharibans, the company has developed a groundbreaking non-invasive diagnostic solution that resembles an ‘ECG for the gut’. This pioneering platform employs a wireless reader and a flexible array of sensors strategically placed on the abdomen to monitor gut electrical signals during gastric emptying. The technology promises to transform how gastroenterologists diagnose and treat complex gastrointestinal issues, streamlining the diagnostic process for patients suffering from abdominal pain and other related symptoms.

In 2024, Alimetry successfully secured $30 million in a Series A Expansion Round led by GD1, alongside several notable investors including IP Group, Auckland UniServices, Movac, K1W1, Icehouse Ventures, Olympus Innovation Ventures, and the Australian Superannuation Fund Hostplus. The investment aims to accelerate the company's vision of enhancing gastroenterology diagnostics and providing patients with faster, more accurate means of diagnosis.

Industry Overview in New Zealand

The healthcare technology sector in New Zealand is thriving, with a growing focus on digital health solutions and telemedicine driven by the increasing demand for efficient diagnostics and treatme